Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
From a Dutch societal perspective, over a lifetime horizon, nirmatrelvir/ritonavir is cost-effective versus BSC in the three groups analysed.
Authors
- Roy Spijkerman (ORCID: https://orcid.org/0000-0002-3620-5433)
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Michel L. Peters
- Carlos Duarte
- Michelle H. M. de Goeij
Institutions
- University of Groningen (NL)
- Pfizer (Netherlands) (NL)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1186/s12962-025-00604-0
- Citations
- 2
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Pfizer